News
December 2011ICON7 Progression Free Survival and interim Overall Survival results were published in the New England Journal of Medicine on 29th December 2011.
Original Article, N Engl J Med 2011 ; 365 : 2484 - 2496
September 2011
ICON7 Quality of Life results were presented at ECCO/ESMO in Stockholm on Monday 26th September 2011.
View QOL Presentation
June 2011
ICON7 Interim overall survival results were presented at ASCO in Chicago on Saturday 4th June 2011.
View ASCO Presentation
Read the updated lay summary
October 2010
ICON7 Progression Free Survival Results!
ICON7 Progression Free Survival Results will be presented at the ESMO conference in Milan on Monday 11th October 2010, the slides presented at this meeting will be available on this website from Tuesday 12th October 2010. A lay summary is now available for all those who have an involvement in ovarian cancer, please click the link below.
Lay summary
View ESMO presentation
Thank you to all ICON7 sites and collaborators, for your continued hard work and effort.
March 2009
End of Recruitment
ICON7 closed to recruitment on Monday 16th February, 2009, with a total of 1528 patients, 8 more than our target.
Thank you to all ICON7 sites and collaborators, for your continued hard work and effort.
January 2009
Recruitment Update
We now have over 1440 patients randomised to the trial, with September 2008 being our best month for recruitment so far, with 96 patients randomised. Thank you to all the sites for their hard work with recruiting patients into ICON7.
End of Recruitment
The last day on which patients may be randomised to ICON7 is Monday 16th February, 2009. We recommend that informed consent for all patients currently in pre-screening is obtained 2 weeks prior to 16th February to allow sufficient time for screening procedures to be carried out.
Sites and groups will not be able to randomise after the end of 16th February 2009
June 2008
Recruitment Update
We now have over 800 patients randomised to the trial, with May 2008 being our best month for recruitment so far, with 88 patients randomised. Thank you to all the sites for their hard work with recruiting patients into ICON7.
First New Zealand Patient Randomised
We are pleased to announce that New Zealand open their first site on 07/04/2008, and had their first patient randomised on 16/04/08.
March 2008
First Spanish Patient Randomised
We are pleased to announce that Spain randomised their first patient on 29/02/08.
January 2008
ICON7 Open in Spain
ICON7 opened to recruitment in Spain in December 2007.
October 2007
Welcome Zeinab Mulla has now joined the MRC ICON7 Team as the ICON7 Trial Manager.
September 2007
ICON7 Open in 3 more countries
ICON7 is now open to recruitment in Australia, Norway and Sweden.
July 2007
First Scandinavian and Canadian Patients Randomised
We are pleased to announce that Denmark randomised their first patient on 27/06/07, Finland on 19/07/07, and Canada on 27/07/07.
May 2007
Welcome Laura Van Dyck and Julie Bakobaki have now joined the MRC ICON7 Team. Laura is the new Data Manager and Julie the Senior Trial Manager.
ICON7 Open in Finland and Denmark
ICON7 is now open to recruitment in Finland and Denmark.
April 2007
Thanks and Goodbye!
Andrew Mazur and Sarah Beall will be leaving the MRC ICON7 Team at the end of April.
We would like to take this opportunity to thank everyone we have worked with on ICON7 for your hard work and wish you continued success with the trial.
March 2007
ICON7 Open and recruiting in France and Germany
ICON7 is now open to recruitment in France and Germany, with the first patient being randomised in Germany on the 27/03/07.
January 2007
UK Clinical Sites Update
In the UK, ICON7 is limited to a maximum of 50 Clinical Sites. All these sites have now been selected and are either open to recruitment or are in the process of applying for local approval.
Any other UK Clinical Sites which are interested in taking part in ICON7 may still register their interest through the website and if any spaces become available we will contact you immediately.
December 2006
First ICON7 Patient Randomised
The ICON7 Team is delighted to announce that the first patient has been entered into the ICON7 trial.
She was randomised on Monday 18th December at St James's University Hospital, Leeds.
This is a significant achievement and we would like to take this opportunity to thank every one who has been involved in setting up the ICON7 trial.
We now look forward to randomising more patients in the UK and opening the trial worldwide in early 2007.
November 2006
UK Institution and Investigator selection process begins
We are delighted to inform you that ICON7 has been approved by UK Central Ethics (London MREC) and the UK Regulatory Authority (MHRA).
We are now in a position to accredit our UK sites and start randomising patients into the trial.
A total of 50 UK centres have been contacted with COREC part C and password for the member’s area of the website to download all relevant documents.
For those investigational sites that have yet to register interest with the MRC, please fill in your contact details on the 'Register Interest' page.
September 2006
MRC ICON7 trial CTA approval of amendment
MHRA has accepted the application for amendment Clinical Trial Authorisation received on 25 August 2006.
Copy of the notice of acceptance of amendment can be downloaded from the member's area.
September 2006
MRC ICON7 trial COREC approval
London MREC reviewed the application and has given the favourable ethical opinion for the MRC ICON7 trial.
Copy of the ethics approval letter can be downloaded from the member's area.
July 2006
MRC ICON7 trial CTA approval
MHRA has accepted the application for Clinical Trial Authorisation to carry out a clinical trial of medicinal product (Bevacizumab).
Copy of the notice of approval can be downloaded from the member's area.
July 2006
ICON7 Launch Meeting
In July, MRC Clinical trials unit’s ICON7 team held it’s Launch Meeting at the Brunei Gallery, SOAS, Russell Square in London. Some 100 investigators, research nurses, trial coordinators and representatives from ROCHE and Patient group –Ovacome attended the 1 day event. The launch meeting featured a number of excellent speakers; Prof Max Parmar (Head of Cancer Division, MRC CTU), Dr Tim Perren (ICON7 Chief Investigator), Dr Fiona Collinson (ICON7 Trial Physician), Andrew Mazur and Sarah Beall (MRC CTU ICON7 team), Prof Gordon Jayson (ICON7 Translational Research subgroup Lead) and Dr Dan Stark (ICON7 QoL subgroup Lead). Electronic copies of the slides are available on the members area of our website.